Get started
Pieris Pharmaceuticals, Inc.Pieris Pharmaceuticals, Inc.Pieris Pharmaceuticals, Inc.

Pieris Pharmaceuticals, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Seasonals

PIRS chart


Full chart

PIRS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪21.82 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−19.13 USD
Net income (FY)
‪−24.54 M‬ USD
Revenue (FY)
‪42.81 M‬ USD
Shares float
‪1.32 M‬
Beta (1Y)
−0.75

Employees


Employees (FY)
50
Change (1Y)
−94 −65.28%
Revenue / Employee (1Y)
‪856.20 K‬ USD
Net income / Employee (1Y)
‪−490.86 K‬ USD

About Pieris Pharmaceuticals, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Stephen S. Yoder
Website
pieris.com
Headquarters
Boston
Founded
2001
FIGI
BBG0055C3N57
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

PIRS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of PIRS is 16.48 USD — it has decreased by −1.35% in the past 24 hours. Watch Pieris Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Pieris Pharmaceuticals, Inc. stocks are traded under the ticker PIRS.
PIRS stock has fallen by −3.06% compared to the previous week, the month change is a 1.85% rise, over the last year Pieris Pharmaceuticals, Inc. has showed a −27.36% decrease.
PIRS reached its all-time high on Feb 13, 2018 with the price of 780.00 USD, and its all-time low was 6.20 USD and was reached on Jul 12, 2024. View more price dynamics on PIRS chart.
See other stocks reaching their highest and lowest prices.
PIRS stock is 2.11% volatile and has beta coefficient of −0.75. Track Pieris Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Pieris Pharmaceuticals, Inc. there?
Today Pieris Pharmaceuticals, Inc. has the market capitalization of ‪21.76 M‬, it has decreased by −0.76% over the last week.
Yes, you can track Pieris Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Pieris Pharmaceuticals, Inc. is going to release the next earnings report on Nov 8, 2024. Keep track of upcoming events with our Earnings Calendar.
PIRS net income for the last quarter is ‪−3.59 M‬ USD, while the quarter before that showed ‪−4.89 M‬ USD of net income which accounts for 26.61% change. Track more Pieris Pharmaceuticals, Inc. financial stats to get the full picture.
No, PIRS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 8, 2024, the company has 50.00 employees. See our rating of the largest employees — is Pieris Pharmaceuticals, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Pieris Pharmaceuticals, Inc. EBITDA is ‪−11.42 M‬ USD, and current EBITDA margin is −32.85%. See more stats in Pieris Pharmaceuticals, Inc. financial statements.
Like other stocks, PIRS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Pieris Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Pieris Pharmaceuticals, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Pieris Pharmaceuticals, Inc. stock shows the sell signal. See more of Pieris Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.